SLFN11 enhances cisplatin sensitivity in pediatric cancer via activation of stress-response and suppression of survival pathways.
The study reports that epigenetically regulated SLFN11 has tumour-context-dependent prognostic associations and that its CRISPR-dCas9-mediated activation sensitizes three pediatric solid-tumour cell lines to cisplatin and talazoparib while altering DNA-damage-response and MAPK signalling.
Open original publication →What the AI sees
The study reports that epigenetically regulated SLFN11 has tumour-context-dependent prognostic associations and that its CRISPR-dCas9-mediated activation sensitizes three pediatric solid-tumour cell lines to cisplatin and talazoparib while altering DNA-damage-response and MAPK signalling.
Research significance
The supplied evidence shows in-vitro enhancement of cisplatin and talazoparib sensitivity after SLFN11 activation; it therefore supports, but does not clinically establish, the hypothesis that measuring or restoring SLFN11 activity could help select or resensitize some pediatric solid tumours for DNA-damaging therapy or PARP inhibition.
Source abstract
BACKGROUND: Paediatric cancers pose treatment challenges due to biological heterogeneity and variable chemotherapy responses. SLFN11, a DNA/RNA helicase-like protein known to sensitise adult tumours to DNA-damaging agents, remains underexplored in paediatric malignancies. METHODS: We examined SLFN11 in Wilms tumour, osteosarcoma, and medulloblastoma using bioinformatics, epigenetic profiling and functional assays. Public datasets (TARGET, ICGC) were analysed to assess SLFN11 expression in relation to survival. Paediatric cancer cell lines were evaluated for baseline expression and promoter methylation. CRISPR-dCas9-mediated activation was used to restore SLFN11, and chemosensitivity was tested with cisplatin and the PARP inhibitor talazoparib. Transcriptomic profiling under cisplatin exposure was performed to identify pathways regulated by SLFN11. RESULTS: SLFN11 showed tumour type-specific correlations with patient outcome, acting as a positive, negative, or neutral predictor depending on cancer context. Promoter methylation regulated SLFN11 expression in paediatric cancers similarly to adult tumours. SLFN11 activation sensitised all three functionally tested cell lines to cisplatin and talazoparib, with transcriptomics showing its role in DNA damage response and MAPK signalling to enhance chemotherapy cytotoxicity. CONCLUSION: In paediatric solid tumours, SLFN11 is a potential predictive biomarker of treatment response. Its ability to dictate the DNA damage landscape through epigenetic modulation highlights its significance as a target for overcoming chemoresistance and improving therapeutic efficacy in young patients. SLFN11 functions as a context-dependent biomarker of outcome and chemotherapy response in paediatric solid tumours. Its epigenetic regulation and modulation of DNA damage highlights SLFN11 as a therapeutic target to overcome chemoresistance.